Phase 2 Trial of Single Agent Ifosfamide/Mesna in Patients with Platinum/Paclitaxel Refractory Ovarian Cancer Who Have Not Previously Been Treated with an Alkylating Agent
- 1 August 1998
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 70 (2), 272-274
- https://doi.org/10.1006/gyno.1998.5065
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.Journal of Clinical Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- A Phase 2 Trial of Ifosfamide/Mesna as Salvage Therapy in Patients with Ovarian Cancer Refractory to or Relapsing after Prior Platinum-Containing ChemotherapyGynecologic Oncology, 1995
- Cancer of the OvaryNew England Journal of Medicine, 1993
- Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.Journal of Clinical Oncology, 1992
- Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.Journal of Clinical Oncology, 1991